Sign In
Buy PFE
$24.48
+0.310 (+1.28%)
At Close: Jul 13, 2026
Pfizer (PFE) Advances While Market Declines: Some Information for Investors
06:45pm, Monday, 13'th Jul 2026
In the latest trading session, Pfizer (PFE) closed at $24.48, marking a +1.28% move from the previous day.
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap?
04:47pm, Monday, 13'th Jul 2026
Abbott Laboratories (NYSE: ABT | ABT Price Prediction) and Pfizer (NYSE: PFE) both delivered Q1 2026 beats, yet the market treats them differently.
How To Build A $50,000 Dividend Portfolio In Today's Market
01:45pm, Monday, 13'th Jul 2026
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (July 2026)
08:15am, Saturday, 11'th Jul 2026
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter
Pfizer: The AI Hedge That Pays You To Stay Defensive
07:09am, Saturday, 11'th Jul 2026
Pfizer remains an undervalued diversification play, underperforming the benchmark but increasing 2% since prior coverage. I view PFE as a defensive holding that pays investors to maintain a cautious s
July Graham Value All-Stars (GVAS) Emit 10 Beaming Buys
06:01am, Saturday, 11'th Jul 2026
July's GVAS Dogs list highlights ten fair-priced, high-yield large-cap stocks, including IRSA Inversiones, Weibo, Verizon, and AT&T, as ideal buys. Analyst targets project average net gains of 40.39%
Pfizer: The Post-Pandemic Turnaround Is Already Underway
05:45am, Saturday, 11'th Jul 2026
Pfizer is undervalued, trading at just over 8x 2026 earnings, with a 7% dividend yield and improving core business fundamentals. Core business excluding COVID drugs grew 7% in Q1, and newly launched/a
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market?
07:15pm, Friday, 10'th Jul 2026
Pfizer has regrouped in the GLP-1 space and is now working on a long-acting drug option. The company's update on the drug's development progress suggests it can compete with GLP-1 drugs from Eli Lilly
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Friday, 10'th Jul 2026
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that the U.S. Food and Drug Administra
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:56am, Friday, 10'th Jul 2026
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait
08:40am, Friday, 10'th Jul 2026
McDonald's (NYSE:MCD | MCD Price Prediction) versus Pfizer (NYSE:PFE): which one deserves a place in a retirement-focused portfolio right now?
‘It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend
12:25pm, Thursday, 09'th Jul 2026
Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.
3 High-Yield Dividends That Pay You Soon (But You Must Act Quickly)
04:07pm, Wednesday, 08'th Jul 2026
Income investors watching the calendar have a narrow window this week. Three of the market's most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines ar
